Sanofi selects Recursion immunology drug candidate for development
RXRX•Sanofi selected the first development candidate from its research collaboration with Recursion and will fund and lead further development and commercialization. The option triggered a $10 million milestone payment, bringing total upfront and milestone payments to $144 million; Phase 1 trials are expected in 2027.
1. Candidate selected
Sanofi optioned the first development candidate from its research collaboration with Recursion, adding it to its development pipeline. The potential first-in-class oral small molecule was developed using AI-enabled design and targets a pair of targets implicated in inflammatory disease.
2. Payments and next steps
The option triggered a $10 million milestone payment, bringing total upfront and milestone payments under the collaboration to $144 million. Recursion remains eligible for more than $300 million in additional program milestones and average low-double-digit royalties on net sales if the drug is successfully commercialized. Sanofi will fund and lead further development and commercialization, with Phase 1 trials expected in 2027.
